Physician profile

Grace V Kumar

Surgery · Dallas, TX

NPI 1417061045

$36,931.70

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$16,010.80
Travel and Lodging$3,168.08
Food and Beverage$1,391.60
Gift$179.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $36,350.21 2019-2023 Da Vinci Surgical System, Davinci Xi, Da Vinci Sp
Baxter Healthcare $450.00 2019
Conmed Corporation $47.62 2023 Airseal
Vertical Pharmaceuticals, LLC $21.05 2020
Alexion Pharmaceuticals, INC. $19.86 2020
Covidien LP $16.26 2019
Lilly USA, LLC $14.83 2021
Merz North America, INC. $11.87 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Grace V Kumar

$36,931.70

in general payments reported 2019-2025

Years
2019-2023
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/336608/grace-v-kumar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.